

## The Advent of Four-drug Combinations in the Frontline Setting: How Will This Change Current Practice?

### References

1. Durie BGM, Hoering A, Abidi MH, et al. Bortezomib with lenalidomide and dexamethasone versus lenalidomide and dexamethasone alone in patients with newly diagnosed myeloma without intent for immediate autologous stem-cell transplant (SWOG S0777): A randomised, open-label, phase 3 trial. *Lancet*. 2017;389(10068):519-527. doi:10.1016/S0140-6736(16)31594-X
2. Durie BGM, Hoering A, Sexton R, et al. Longer term follow-up of the randomized phase III trial SWOG S0777: Bortezomib, lenalidomide and dexamethasone vs. lenalidomide and dexamethasone in patients (Pts) with previously untreated multiple myeloma without an intent for immediate autologous stem cell transplant (ASCT). *Blood Cancer J*. 2020;10(5):1-11. doi:10.1038/s41408-020-0311-8
3. Dimopoulos MA, Oriol A, Nahi H, et al. Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. *N Engl J Med*. 2016;375(14):1319-1331. doi:10.1056/NEJMoa1607751
4. Kaufman JL, Usmani SZ, San-Miguel J, et al. Four-Year Follow-up of the Phase 3 Pollux Study of Daratumumab Plus Lenalidomide and Dexamethasone (D-Rd) Versus Lenalidomide and Dexamethasone (Rd) Alone in Relapsed or Refractory Multiple Myeloma (RRMM). *Blood*. 2019;134(Supplement\_1):1866-1866. doi:10.1182/blood-2019-123483
5. Attal M, Lauwers-Cances V, Hulin C, et al. Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma. *N Engl J Med*. 2017;376(14):1311-1320. doi:10.1056/NEJMoa1611750
6. O'Donnell EK, Laubach JP, Yee AJ, et al. A phase 2 study of modified lenalidomide, bortezomib and dexamethasone in transplant-ineligible multiple myeloma. *Br J Haematol*. 2018;182(2):222-230. doi:10.1111/bjh.15261
7. Moreau P, Attal M, Hulin C, et al. Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): A randomised, open-label, phase 3 study. *Lancet*. 2019;394(10192):29-38. doi:10.1016/S0140-6736(19)31240-1
8. Voorhees PM, Kaufman JL, Laubach J, et al. Daratumumab, lenalidomide, bortezomib, and dexamethasone for transplant-eligible newly diagnosed multiple myeloma: The GRIFFIN trial. *Blood*. 2020;136(8):936-945. doi:10.1182/blood.2020005288

9. Kapoor P, Gertz MA, Laplant B, et al. Phase 2 Trial of Daratumumab, Ixazomib, Lenalidomide and Modified Dose Dexamethasone in Patients with Newly Diagnosed Multiple Myeloma. *Blood*. 2019;134(Supplement\_1):864-864. doi:10.1182/blood-2019-131476
10. Yimer H, Melear J, Faber E, et al. Daratumumab, bortezomib, cyclophosphamide and dexamethasone in newly diagnosed and relapsed multiple myeloma: LYRA study. *Br J Haematol*. 2019;185(3):492-502. doi:10.1111/bjh.15806
11. Mateos M-V, Cavo M, Blade J, et al. Overall survival with daratumumab, bortezomib, melphalan, and prednisone in newly diagnosed multiple myeloma (ALCYONE): A randomised, open-label, phase 3 trial. *Lancet*. 2020;395(10218):132-141. doi:10.1016/S0140-6736(19)32956-3
12. ClinicalTrials.gov. A Phase 3 Randomized, Open-Label, Multicenter Study Assessing the Clinical Benefit of Isatuximab (SAR650984) in Combination With Bortezomib (Velcade®), Lenalidomide (Revlimid®) and Dexamethasone Versus Bortezomib, Lenalidomide and Dexamethasone in Patients With Newly Diagnosed Multiple Myeloma (NDMM) Not Eligible for Transplant. clinicaltrials.gov; 2020. Accessed March 4, 2021. <https://clinicaltrials.gov/ct2/show/NCT03319667>
13. Usmani SZ, Hoering A, Ailawadhi S, et al. Bortezomib, lenalidomide, and dexamethasone with or without elotuzumab in patients with untreated, high-risk multiple myeloma (SWOG-1211): Primary analysis of a randomised, phase 2 trial. *Lancet Haematol*. 2021;8(1):e45-e54. doi:10.1016/S2352-3026(20)30354-9
14. van de Donk N. Sequencing multiple myeloma therapies with and after antibody therapies. *Hematology Am Soc Hematol Educ Program*. 2020;2020(1):248-258. doi:10.1182/hematology.2020000109.
15. ClinicalTrials.gov. A Phase 3 Study Comparing Daratumumab, VELCADE (Bortezomib), Lenalidomide, and Dexamethasone (D-VRd) With VELCADE, Lenalidomide, and Dexamethasone (VRd) in Subjects With Untreated Multiple Myeloma and for Whom Hematopoietic Stem Cell Transplant Is Not Planned as Initial Therapy. clinicaltrials.gov; 2021. Accessed March 4, 2021. <https://clinicaltrials.gov/ct2/show/NCT03652064>
16. ECOG-ACRIN Cancer Research Group. Effective Quadruplet Utilization After Treatment Evaluation (EQUATE): A Randomized Phase 3 Trial for Newly Diagnosed Multiple Myeloma Not Intended for Early Autologous Transplantation. clinicaltrials.gov; 2021. Accessed March 4, 2021. <https://clinicaltrials.gov/ct2/show/NCT04566328>
17. Kumar S, Paiva B, Anderson KC, et al. International Myeloma Working Group consensus criteria for response and minimal residual disease assessment in multiple myeloma. *Lancet Oncol*. 2016;17(8):e328-e346. doi:10.1016/S1470-2045(16)30206-6

18. Landgren O, Devlin S, Boulad M, Mailankody S. Role of MRD status in relation to clinical outcomes in newly diagnosed multiple myeloma patients: A meta-analysis. *Bone Marrow Transplant.* 2016;51(12):1565-1568. doi:10.1038/bmt.2016.222
19. Munshi NC, Avet-Loiseau H, Rawstron AC, et al. Association of Minimal Residual Disease With Superior Survival Outcomes in Patients With Multiple Myeloma: A Meta-analysis. *JAMA Oncol.* 2017;3(1):28-35. doi:10.1001/jamaoncol.2016.3160
20. ClinicalTrials.gov. Optimizing Prolonged Treatment in Myeloma Using MRD Assessment (OPTIMUM). clinicaltrials.gov; 2020. Accessed March 4, 2021. <https://clinicaltrials.gov/ct2/show/NCT03941860>
21. ClinicalTrials.gov. S1803, Phase III Study of Daratumumab/RHuPH20 (NSC-810307) + Lenalidomide or Lenalidomide as Post-Autologous Stem Cell Transplant Maintenance Therapy in Patients With Multiple Myeloma (MM) Using Minimal Residual Disease to Direct Therapy Duration (DRAMMATIC Study). clinicaltrials.gov; 2021. Accessed March 4, 2021. <https://clinicaltrials.gov/ct2/show/NCT04071457>
22. Costa LJ, Chhabra S, Godby KN, et al. Daratumumab, Carfilzomib, Lenalidomide and Dexamethasone (Dara-KRd) Induction, Autologous Transplantation and Post-Transplant, Response-Adapted, Measurable Residual Disease (MRD)-Based Dara-Krd Consolidation in Patients with Newly Diagnosed Multiple Myeloma (NDMM). *Blood.* 2019;134(Supplement\_1):860-860. doi:10.1182/blood-2019-123170
23. Hulin C, Moreau P, Attal M, et al. Stem cell (SC) yield and transplantation results from transplant-eligible newly diagnosed multiple myeloma (TE NDMM) patients (pts) receiving daratumumab (DARA) + bortezomib/thalidomide/dexamethasone (D-VTd) in the phase 3 CASSIOPEIA study. *Haematologica.* 2021 Mar 4. doi: 10.3324/haematol.2020.261842. Online ahead of print.